FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309267666> ?p ?o ?g. }

• W4309267666 endingPage "43179" @default.
• W4309267666 startingPage "43169" @default.
• W4309267666 abstract "Regulation of lipoxygenase (LOX) activity is of great interest due to the involvement of the various LOX isoforms in the inflammatory process and hence many diseases. The bulk of investigations have centered around the discovery and design of inhibitors. However, the emerging understanding of the role of h15-LOX-1 in the resolution of inflammation provides a rationale for the development of activators as well. Bicyclic pyrazolines are known bioactive molecules that have been shown to display antibiotic and anti-inflammatory activities. In the current work, we reevaluated a previously discovered bicyclic pyrazoline h15-LOX-1 activator, PKUMDL_MH_1001 (written as 1 for this publication), and determined that it is inactive against other human LOX isozymes, h5-LOX, h12-LOX, and h15-LOX-2. Analytical characterization of 1 obtained in the final synthesis step identified it as a mixture of cis- and trans-diastereomers: cis-1 (12%) and trans-1 (88%); and kinetic analysis indicated similar potency between the two. Using compound 1 as the cis–trans mixture, h15-LOX-1 catalysis with arachidonic acid (AA) (AC50 = 7.8 +/– 1 μM, Amax = 240%) and linoleic acid (AC50 = 5.3 +/– 0.7 μM, Amax = 98%) was activated, but not with docosahexaenoic acid (DHA) or mono-oxylipins. Steady-state kinetics demonstrate V-type activation for 1, with a β value of 2.2 +/– 0.4 and an Kx of 16 +/– 1 μM. Finally, it is demonstrated that the mechanism of activation for 1 is likely not due to decreasing substrate inhibition, as was postulated previously. 1 also did not affect the activity of the h15-LOX-1 selective inhibitor, ML351, nor did 1 affect the activity of allosteric effectors, such as 12S-hydroxy-5Z,8Z,10E,14Z-eicosatetraenoic acid (12S-HETE) and 14S-hydroperoxy-4Z,7Z,10Z,12E,16Z,19Z-docosahexaenoic acid (14S-HpDHA). These data confirm that 1 binds to a distinct activation binding site, as previously postulated. Future work should be aimed at the development of selective activators that are capable of activating h15-LOX-1 catalysis with DHA, thus enhancing the production of DHA-derived pro-resolution biomolecules." @default.
• W4309267666 created "2022-11-25" @default.
• W4309267666 creator A5016247682 @default.
• W4309267666 creator A5040591040 @default.
• W4309267666 creator A5040684075 @default.
• W4309267666 creator A5041644296 @default.
• W4309267666 creator A5049319108 @default.
• W4309267666 creator A5056127969 @default.
• W4309267666 creator A5060834723 @default.
• W4309267666 creator A5089351110 @default.
• W4309267666 date "2022-11-17" @default.
• W4309267666 modified "2023-10-18" @default.
• W4309267666 title "Reevaluation of a Bicyclic Pyrazoline as a Selective 15-Lipoxygenase V-Type Activator Possessing Fatty Acid Specificity" @default.
• W4309267666 cites W135027921 @default.
• W4309267666 cites W1497700962 @default.
• W4309267666 cites W1591803765 @default.
• W4309267666 cites W1941276656 @default.
• W4309267666 cites W1966325240 @default.
• W4309267666 cites W1973025028 @default.
• W4309267666 cites W1989856248 @default.
• W4309267666 cites W1991954470 @default.
• W4309267666 cites W1996649892 @default.
• W4309267666 cites W2011022262 @default.
• W4309267666 cites W2028705982 @default.
• W4309267666 cites W2030126029 @default.
• W4309267666 cites W2030431061 @default.
• W4309267666 cites W2033256909 @default.
• W4309267666 cites W2050568232 @default.
• W4309267666 cites W2059290365 @default.
• W4309267666 cites W2064315249 @default.
• W4309267666 cites W2065377708 @default.
• W4309267666 cites W2074203890 @default.
• W4309267666 cites W2076898547 @default.
• W4309267666 cites W2090515045 @default.
• W4309267666 cites W2090609282 @default.
• W4309267666 cites W2153531663 @default.
• W4309267666 cites W2157374284 @default.
• W4309267666 cites W2162465757 @default.
• W4309267666 cites W2164699777 @default.
• W4309267666 cites W2176487670 @default.
• W4309267666 cites W2315873193 @default.
• W4309267666 cites W2316344275 @default.
• W4309267666 cites W2464362473 @default.
• W4309267666 cites W2749918768 @default.
• W4309267666 cites W2769547962 @default.
• W4309267666 cites W2799633991 @default.
• W4309267666 cites W2898401907 @default.
• W4309267666 cites W2950173628 @default.
• W4309267666 cites W3020335344 @default.
• W4309267666 cites W3043876390 @default.
• W4309267666 cites W3164297032 @default.
• W4309267666 cites W3211858634 @default.
• W4309267666 cites W53123824 @default.
• W4309267666 doi "https://doi.org/10.1021/acsomega.2c05877" @default.
• W4309267666 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36467910" @default.
• W4309267666 hasPublicationYear "2022" @default.
• W4309267666 type Work @default.
• W4309267666 citedByCount "0" @default.
• W4309267666 crossrefType "journal-article" @default.
• W4309267666 hasAuthorship W4309267666A5016247682 @default.
• W4309267666 hasAuthorship W4309267666A5040591040 @default.
• W4309267666 hasAuthorship W4309267666A5040684075 @default.
• W4309267666 hasAuthorship W4309267666A5041644296 @default.
• W4309267666 hasAuthorship W4309267666A5049319108 @default.
• W4309267666 hasAuthorship W4309267666A5056127969 @default.
• W4309267666 hasAuthorship W4309267666A5060834723 @default.
• W4309267666 hasAuthorship W4309267666A5089351110 @default.
• W4309267666 hasBestOaLocation W43092676661 @default.
• W4309267666 hasConcept C104317684 @default.
• W4309267666 hasConcept C178790620 @default.
• W4309267666 hasConcept C181199279 @default.
• W4309267666 hasConcept C185592680 @default.
• W4309267666 hasConcept C24961977 @default.
• W4309267666 hasConcept C2778078955 @default.
• W4309267666 hasConcept C2780744904 @default.
• W4309267666 hasConcept C2780809830 @default.
• W4309267666 hasConcept C2780857362 @default.
• W4309267666 hasConcept C543025807 @default.
• W4309267666 hasConcept C55493867 @default.
• W4309267666 hasConcept C71240020 @default.
• W4309267666 hasConcept C88045685 @default.
• W4309267666 hasConceptScore W4309267666C104317684 @default.
• W4309267666 hasConceptScore W4309267666C178790620 @default.
• W4309267666 hasConceptScore W4309267666C181199279 @default.
• W4309267666 hasConceptScore W4309267666C185592680 @default.
• W4309267666 hasConceptScore W4309267666C24961977 @default.
• W4309267666 hasConceptScore W4309267666C2778078955 @default.
• W4309267666 hasConceptScore W4309267666C2780744904 @default.
• W4309267666 hasConceptScore W4309267666C2780809830 @default.
• W4309267666 hasConceptScore W4309267666C2780857362 @default.
• W4309267666 hasConceptScore W4309267666C543025807 @default.
• W4309267666 hasConceptScore W4309267666C55493867 @default.
• W4309267666 hasConceptScore W4309267666C71240020 @default.
• W4309267666 hasConceptScore W4309267666C88045685 @default.
• W4309267666 hasFunder F4320337354 @default.
• W4309267666 hasIssue "47" @default.
• W4309267666 hasLocation W43092676661 @default.
• W4309267666 hasLocation W43092676662 @default.

• next